ERBB2 and breast cancer: These in situ data further confirmed the aggressive breast cancer phenotypes recorded in ER/PR-positive, HER2-negative, and miRNA-overexpressing MCF7-miR526b and MCF7-miR655 cell lines under hypoxia in the present article.